Ionis Pharmaceuticals

Ionis Pharmaceuticals

Yahoo Finance • 11 hours ago

Panic grips Ionis Pharmaceuticals investors amid bad news spree

A single failed trial can undo years of work in one trading session, and Ionis Pharmaceuticals (IONS) just went through both consecutively. Ionis Pharmaceuticals lost nearly a quarter of its value on July 9 after its heart drug Wainua fai... Full story

Yahoo Finance • 2 days ago

Ionis Pharmaceuticals is Now Oversold (IONS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 3 days ago

Ionis extends losses as Roche scraps two partnered studies

[Roche Diagnostics campus facade in Silicon Valley] Michael Vi/iStock Editorial via Getty Images Shares of Ionis Pharmaceuticals (IONS [https://seekingalpha.com/symbol/IONS]) continued to trade lower on Friday after Roche (RHHBY [https://... Full story

Yahoo Finance • 3 days ago

Cathie Wood Dumps AMD, Doubles Down on Meta Stock

This article first appeared on GuruFocus. Cathie Wood's ARK added to its Meta Platforms (NASDAQ:META) position while further reducing its stake in Advanced Micro Devices (NASDAQ:AMD), according to the firm's daily trade disclosure release... Full story

Yahoo Finance • 3 days ago

Ionis Pharmaceuticals reiterates FY26 outlook, unchanged from April projections

Ionis Pharmaceuticals (IONS [https://seekingalpha.com/symbol/IONS]) has reiterated [https://seekingalpha.com/filing/309816327] its previously issued financial outlook for the full fiscal year ending December 31, 2026. The corporate guidan... Full story

Yahoo Finance • 3 days ago

Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump

AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing. Continue Reading... Full story

Yahoo Finance • 3 days ago

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 days ago

AstraZeneca Slides 9.9% After Heart Drug Trial Misses Late-Stage Goal

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), a UK drugmaker known for its cancer medicines, faced a rare clinical setback after Wainua, a gene-silencing heart drug it is developing with Ionis Pharmaceuticals, a Califo... Full story

Yahoo Finance • 3 days ago

Strength in Chipmakers Boosts Stock Indexes

The S&P 500 Index ($SPX) (SPY) today is up +0.48%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.26%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.27%.  September E-mini S&P futures (ESU26) are up +0.49%, and September E-mini... Full story

Yahoo Finance • 3 days ago

FTSE 100 held back by AstraZeneca trial setback

Heavy falls in AstraZeneca saw London's FTSE 100 underperform European peers, while investors continue to weigh up developments in the Middle East. The FTSE 100 closed down 16.59 points, 0.2%, at 10,472.45. The FTSE 250 ended up 222.92 po... Full story

Yahoo Finance • 3 days ago

Stocks Climb on Strength in Chipmakers

The S&P 500 Index ($SPX) (SPY) today is up +0.47%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.14%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.55%.  September E-mini S&P futures (ESU26) are up +0.47%, and September E-mini... Full story

Yahoo Finance • 4 days ago

Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump

AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing. Continue Reading... Full story

Yahoo Finance • 4 days ago

AstraZeneca Falls After Wainua Heart Disease Trial Fails

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN) fell 8.71% intraday after the British-Swedish drugmaker disclosed that the Phase III CARDIO-TTRansform trial of Wainua (eplontersen), co-developed with Ionis Pharmaceuticals... Full story

Yahoo Finance • 4 days ago

Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/ Ionis

Oselote/iStock via Getty Images Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Alnylam Pharma (ALNY [https://seekingalpha.com/symbol/ALNY]), and BridgeBio Pharma (BBIO [https://seekingalpha.com/symbol/BBIO]), which market drugs for a... Full story

Yahoo Finance • 4 days ago

Ionis And AstraZeneca's CARDIO-TTRansform Trial Of Eplontersen In ATTR-CM Misses Primary Endpoint

(RTTNews) - Ionis Pharmaceuticals Inc. (IONS) and AstraZeneca announced results from the Phase 3 CARDIO-TTRansform trial of Eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The study did not meet its prim... Full story

Yahoo Finance • 4 days ago

AstraZeneca tumbles as heart drug trial misses main efficacy goal

[AstraZeneca company office building] Robert Way AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) shares tumbled nearly 10% in London after a late-stage trial for an experimental heart disease failed to meet its target. The CARDIO... Full story

Yahoo Finance • 4 days ago

Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy

– Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV events; in a pre-specified subgroup analysis, a nominally significant result was observed with eplontersen monotherapy – – Favorable sa... Full story

Yahoo Finance • 7 days ago

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome

- Topline data from REVEAL anticipated in 2H 2027 - CARLSBAD, Calif., July 06, 2026--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the glob... Full story

Yahoo Finance • 11 days ago

Ford leads Bank of America's top 10 U.S. ideas in Quant rankings

[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Bank of America has unveiled its top 10 U.S. ideas for the third quarter of 2026, highlighting companies the firm believes are well positioned across a range of sectors, w... Full story

Yahoo Finance • 27 days ago

Is lonis Pharmaceuticals, Inc. (IONS) Among the Best Genomics Stocks to Buy According to Analysts?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On May 28, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) said partner GSK reported pivotal Phase 3 data for bepirovirsen. The corpora... Full story